Skip to main content
Journal cover image

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Publication ,  Journal Article
Kandzari, DE; Hasselblad, V; Tcheng, JE; Stone, GW; Califf, RM; Kastrati, A; Neumann, F-J; Brener, SJ; Montalescot, G; Kong, DF; Harrington, RA
Published in: Am Heart J
March 2004

BACKGROUND: Investigations of glycoprotein (GP) IIb/IIIa inhibition in primary percutaneous coronary intervention (PCI) have suggested the efficacy of abciximab in improving clinical and angiographic outcomes, but sample-size limitations and variability in trial design preclude the ability to generalize these results to a broader patient population. METHODS: Meta-analytic techniques were used to evaluate clinical outcomes from randomized trials comparing GP IIb/IIIa inhibition with placebo or control therapy in primary PCI for acute myocardial infarction (MI). RESULTS: In 3266 patients, treatment with abciximab significantly reduced the 30-day composite end point of death, reinfarction, or ischemic or urgent target-vessel revascularization (TVR; odds ratio [OR], 0.54; 95% CI, 0.40-0.72), with trends toward reduced 30-day death and death or reinfarction. Abciximab resulted in an increased likelihood of major bleeding (OR, 1.74; 95% CI, 1.11-2.72). By 6 months, abciximab significantly reduced the occurrence of death, reinfarction, or any TVR (OR, 0.80; 95% CI, 0.67-0.97), and there were positive trends favoring a decrease in mortality alone and the composite of death or reinfarction. CONCLUSIONS: Treatment with abciximab significantly reduces early adverse ischemic events, a clinical benefit that is maintained at 6-month follow-up. These findings support the use of adjunctive GP IIb/IIIa inhibition in primary PCI.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2004

Volume

147

Issue

3

Start / End Page

457 / 462

Location

United States

Related Subject Headings

  • Stents
  • Recurrence
  • Randomized Controlled Trials as Topic
  • Proportional Hazards Models
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Immunoglobulin Fab Fragments
  • Humans
  • Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kandzari, D. E., Hasselblad, V., Tcheng, J. E., Stone, G. W., Califf, R. M., Kastrati, A., … Harrington, R. A. (2004). Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J, 147(3), 457–462. https://doi.org/10.1016/j.ahj.2003.08.011
Kandzari, David E., Vic Hasselblad, James E. Tcheng, Gregg W. Stone, Robert M. Califf, Adnan Kastrati, Franz-Josef Neumann, et al. “Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.Am Heart J 147, no. 3 (March 2004): 457–62. https://doi.org/10.1016/j.ahj.2003.08.011.
Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004 Mar;147(3):457–62.
Kandzari, David E., et al. “Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.Am Heart J, vol. 147, no. 3, Mar. 2004, pp. 457–62. Pubmed, doi:10.1016/j.ahj.2003.08.011.
Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann F-J, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004 Mar;147(3):457–462.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2004

Volume

147

Issue

3

Start / End Page

457 / 462

Location

United States

Related Subject Headings

  • Stents
  • Recurrence
  • Randomized Controlled Trials as Topic
  • Proportional Hazards Models
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Immunoglobulin Fab Fragments
  • Humans
  • Hemorrhage